Abbott Follows Pfizer To FDA With Co-Developed Lung Cancer Diagnostic

A 2009 collaboration agreement with Pfizer could start bearing fruit for Abbott Molecular by year end, with the firms' lung cancer drug-diagnostic combination now under review at FDA.